US Patent Issued to CRISPR THERAPEUTICS on May 20 for "T-cells expressing anti-LIV1 chimeric antigen receptor" (Massachusetts Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,304,968, issued on May 20, was assigned to CRISPR THERAPEUTICS AG (Zug, Switzerland).

"T-cells expressing anti-LIV1 chimeric antigen receptor" was invented by Jonathan Alexander Terrett (Cambridge, Mass.) and Jason Sagert (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1+ malignancies."

The patent was filed on Nov. 7, 2019, under Application No. 16/677,267.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=...